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Policies to promote shared decision making 
are becoming prominent in the United States, 
Canada, and United Kingdom.1‑3 This is partly 
because of a recognition of the ethical imperative 
to properly involve patients in decisions about 
their care4  5 and partly because of  the accruing 
evidence that the approach has benefits.6 Shared 
decision making is an approach where clinicians 
and patients make decisions together using the 
best available evidence. Patients are encouraged 
to think about the available screening, treatment, 
or management options and the likely benefits 
and harms of each so that they can communi‑
cate their preferences and help select the best 
course of action for them. Shared decision mak‑
ing respects patient autonomy and promotes 
patient en gagement.
Despite considerable interest in shared deci‑
sion making, implementation has proved diffi‑
cult and slow.7 At least three conditions must be 
in place for shared decision making to become 
part of mainstream clinical practice: ready access 
to evidence based information about treatment 
options; guidance on how to weigh up the pros 
and cons of different options; and a supportive 
clinical culture that facilitates patient engage‑
ment. This article outlines some options for cre‑
ating a sustainable decision support platform for 
patients that may facilitate a wider adoption of 
shared decision making in clinical practice.
Decision aids
Interventions to support patient decisions, 
often called decision aids, have been devel‑
oped to provide evidence based information 
to patients.8 These tools are usually designed 
for situations where there is some uncertainty 
about the best treatment option and provide 
information about the harms and benefits in 
as balanced a way as possible. Some tools are 
short and can be used in consultations9; others 
are longer, such as DVDs, booklets, or web tools 
that patients use before consulting a clinician. 
Decision aids are appropriate when more 
than one course of action is feasible (clinical 
equipoise) and where the best decision depends 
on the patient’s reaction to the outcome prob‑
abilities. These are known as “preference sen‑
sitive” decisions.10 Examples include breast 
conservation surgery or mastectomy in early 
breast cancer, treatments for benign prostatic 
hypertrophy or menorrhagia, and managing 
knee osteoarthritis.
Evidence of benefit 
A large number of decision aids are now avail‑
able, most of which were developed in North 
America. The latest iteration of the Cochrane sys‑
tematic review includes 55 trials6 and provides 
evidence that patients who have used these tools 
are better informed (mean difference 15.2/100 
95% confidence interval 11.7 to 18.7) and less 
passive in decision making (relative risk 0.6, 
0.5 to 0.8). There is some evidence that when 
patients have made well informed decisions, 
they also adhere better to treatment regimens11 
and that when informed patients face discretion‑
ary surgery, they make more conservative deci‑
sions, often deferring or declining interventions 
(relative risk 0.8, 0.6 to 0.9).6 These effects seem 
to be strengthened when patients are given deci‑
sion coaching (a brief discussion with a trained 
facilitator) to help them with the process of 
 deliberation.12  13
In short, there is consistent evidence that deci‑
sion support interventions designed for patients 
ensure that the ethical imperative of informed 
patient choice and consent is met, with a range 
of benefits for patients. In some examples, espe‑
cially where there are choices between more 
and less invasive options, these may lead to cost 
reductions; the Cochrane review of decision aids 
found that, in some contexts, they could reduce 
rates of elective surgery by 25%. This means 
that the NHS might be able to save considerable 
amounts if shared decision making, supported 
by decision support, could be achieved before 
common elective surgical procedures. Shared 
decision making might also reduce the likelihood 
and cost of litigation, although there is no formal 
evidence for this yet.
Putting tools into practice
The pioneer in setting up an organisation based 
system for implementing shared decision mak‑
ing is the Dartmouth‑Hitchcock Medical Center 
in New Hampshire, which is linked to Dartmouth 
College. Eleven years ago, it started using deci‑
sion support tools produced by the Foundation 
for Informed Decision Making in Boston for a few 
important areas such as breast cancer, ortho‑
paedics, and urology. Today, its Shared Decision 
Making Center has over 30 DVD based patient 
decision support tools.14 Many of the centre’s 
clinicians have integrated these tools into their 
workflows and electronic records, reporting that 
consulting with patients after they have had an 
opportunity to use the tools enhances the clini‑
cal encounter.
Since its launch in 1999, the centre has 
loaned 24 750 video, paper, and electronic 
decision aids for use by patients and review by 
clinicians. Despite its local success, the centre 
remains unique in the United States, although 
other implementation projects are in progress in 
primary care and other settings.
The NHS has a longstanding interest in 
decision aids and has invested in piloting and 
adapting the tools developed by the Founda‑
tion for Informed Decision Making for prostate 
cancer, benign prostatic hypertrophy, and osteo‑
arthritis of the knee.15 Anglicised adaptations 
of the DVDs and patient booklets have been 
distributed to urology departments throughout 
England, and the programme is being publi‑
cised at conferences and specialty meetings. In 
addition, the NHS Screening and Cancer Screen‑
ing Programmes and Cancer Research UK have 
worked with the decision laboratory at Cardiff 
University to develop web based decision sup‑
port for patients considering being tested for 
prostate specific cancer antigen (Prosdex, www.
prosdex.com 16) or facing a decision whether to 
have mastectomy or breast conserving surgery 
(Bresdex, www.bresdex.com). These initiatives 
are important, but the tools are not sufficient on 
their own. The next challenge is how to embed 
shared decision making and the use of patient 
decision support in the fabric of the NHS.
Implementation strategies
The Health Foundation has funded a  programme 
to learn more about how to achieve a wider 
implementation of shared decision making.17 
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This initiative coincides with the efforts by the 
East of England Strategic Health Authority, 
commissioned by the Department of Health, to 
accelerate the adoption of patient decision sup‑
port as a means of implementing shared decision 
making. The health authority has commissioned 
NHS Direct to pilot three web based patient deci‑
sion support tools. The decision aids, produced 
originally by the Foundation for Informed Deci‑
sion Making, have been adapted for online use by 
patients with osteoarthritis of the knee, benign 
prostatic hypertrophy, and prostate cancer. Eight 
NHS pilot sites have been chosen and asked to 
identify patients who have been referred for 
specialist advice and who are at key treatment 
decision points. These patients are asked to 
access the interactive web based decision sup‑
port system before they attend their outpatient 
appointment so that they are better informed 
(figure). Patients who do not have access to the 
internet are provided with a telephone number 
for information advisers at NHS Direct, who will 
also post them a copy of equivalent information. 
While using the interactive system, patients are 
asked to complete a survey to gauge the sever‑
ity of their symptoms and their initial treatment 
preferences. This is summarised and available 
to them and their c linician at a later date. The 
logistics, feasibility, and effect of this approach 
are being evaluated.
For conditions that can be diagnosed reliably 
in general practice, it might be more appropri‑
ate to make patient decision support available 
before referral, perhaps by embedding them in 
primary care electronic health record systems. 
Providers of supplementary information, such 
as the Map of Medicine, could provide decision 
support for patients alongside the evidence 
based decision support they provide for clini‑
cians. For other health problems where self care 
is a feasible option, information providers such 
as NHS Choices could include decision support 
in their public facing websites. Commissioning 
consortiums might want to ensure that decision 
coaching is provided as part of telecare services 
for people with long term conditions. Together, 
these various means could make patient deci‑
sion support readily available for a wide range 
of topics.
Organisational culture
Although it is clear that patients desire and 
value information about treatment choices,18  19 
it is difficult to embed the attitudes, skills, and 
interventions into routine practice.7 Many 
b arriers are cited, including concerns about 
insufficient time and lack of fit into organisa‑
tional routines. Professionals often claim that 
there is no need for this approach because 
shared decision making already occurs,7 but 
the available evidence contradicts this asser‑
tion.20  21 The latest results from the Care Qual‑
ity Commission’s national patient surveys show 
that 48% of inpatients and 30% of primary care 
patients would have liked more involvement in 
decisions about their care.19
Research on shared decision making has 
focused mostly on the creation of tools to sup‑
port patient involvement in decisions and much 
less on how to create a culture where profes‑
sionals espouse shared decision making as 
a skill and routinely use these tools. Achiev‑
ing this aim will require multiple approaches, 
including strategies such as social marketing, 
engagement of clinical champions, support 
from other organisational leaders, and meas‑
urement that focuses on relevant aspects of 
patients’ experience such as their degree of 
deliberation and attainment of skills in shared 
decision making.
Challenges to implementation
Substantial challenges still need to be met. 
Producing and updating decision support for 
patients is expensive: it requires meticulous 
attention to the accuracy of evidence as well 
as designing information that is easily under‑
stood by patients with different backgrounds 
and literacy levels. Adapting tools rather than 
re‑inventing would be wise for the NHS given 
the time and resources required. Tools should 
meet a quality standard, and a process to assess 
quality will be required.22
Perhaps the biggest challenge is to ensure 
that decision support materials are accessible 
to both patients and clinicians and that they 
fit into clinical workflows.23 This is important 
because these tools give clinicians access to 
summarised evidence about the harms and 
benefits of options just as much as they provide 
it to patients. Tools that provide short summa‑
ries for use in clinical encounters alongside 
longer sources of information that patients can 
access at home may be more readily adopted 
by  clinicians.8
Building patient decision support into the 
NHS will require substantial investment and a 
collaboration between many agencies. Many of 
the building blocks are in place. High quality 
decision aids for many conditions already exist, 
although it would also be necessary to establish 
a system for regular review and updating. The 
results of the NHS Direct pilot will show whether 
it is possible to build systems that provide use‑
ful links between frontline NHS clinics and tools 
that are hosted online. Success will require 
strong strategic leadership, commissioning of 
high quality content, and the provision of sus‑
tained funding to host these resources using 
computerised, online, or telephone supported 
channels. If such a platform could be created, 
it would go a long way towards developing a 
patient led revolution in health care—one that 
is fuelled by evidence.
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Do patients want a choice and does it work?
The government in England wants to give patients more choice about their healthcare.  
But Angela Coulter argues that treatment choice is more popular with patients 
than provider choice, with much greater evidence of benefit
 “Nothing about me without me” was the guid‑
ing principle adopted by 64 participants from 29 
countries at a 1998 Salzburg global seminar con‑
vened to develop ideas for improving the quality of 
health care by involving patients.1 The catchphrase 
has now resurfaced in the coalition government’s 
new plan for the NHS in England, which sees 
patient choice and shared decision making as key 
mechanisms to create a patient centred and qual‑
ity focused NHS.2 The government wants to extend 
the offer of choice beyond what is currently avail‑
able to include choice of specialist team, choice of 
general practice, and choice of treatment.
The introduction of choice and market competi‑
tion into the NHS has been highly controversial. 
The debate about provider choice centres on its 
effect on quality, service development, equity, and 
patient empowerment (table). Many people have 
argued passionately for and against the policy 
on the basis of their expectations of its effects, 
but research evidence to confirm or refute these 
assumptions is only now beginning to emerge.
In contrast, evidence about the effects of engag‑
ing patients in treatment choices has accumulated 
over some time, but the findings have been largely 
ignored. Although only a small minority of people 
want to switch providers, patient surveys show a 
large unmet demand for greater involvement in 
treatment decisions that has persisted over the past 
eight years (figure). The government’s determina‑
tion to introduce wider choice and shared decision 
making may be challenging to implement.
Choice of specialist
The right to choose where to receive specialist 
care is not a new idea for patients in England. 
After several pilot projects, choice at the point 
of referral was introduced from December 2005. 
Patients could choose where they were referred 
to, rather than an individual specialist, and a 
website, NHS Choices (www.nhs.uk), was set up 
to publish information on quality indicators to 
inform people’s choices. In 2008 the available 
choices were extended to include any hospital 
in the country, including private hospitals, and 
a legal right to choose was enshrined in the NHS 
constitution.3 The latest white paper promises 
that this will be extended to enable patients to 
choose the specialist clinical team that will pro‑
vide their treatment.2
Pilot studies of patients offered a choice while 
on the waiting list for elective surgery showed 
that a choice of treatment location was popular 
and uptake was high. When patients waiting 
for cardiac surgery were offered the choice of 
going to another hospital with a shorter wait‑
ing list, half of them opted to do so, sometimes 
travelling long distances.4 Similarly, a high pro‑
portion (67%) of patients in London awaiting 
various elective surgical procedures opted for 
alternatives to their local hospital when given 
the choice, and there was no evidence of socio‑
economic differences in uptake.5 One of the 
most startling findings from the London patient 
choice pilot study was that over two thirds 
(68%) of those eligible for the scheme were 
not offered the option of going to an alternative 
hospital, pointing to a reluctance on the part 
of clinicians or managers to encourage choice.
Arguments for and against provider choice
Domain For Against
Quality Leads to better patient experience, 
safety, and clinical effectiveness
Increases fragmentation, reduces continuity, undermines 
population based services
Service development Improves access, increases plurality of 
providers, encourages innovation
Increases privatisation, destabilising existing NHS 
providers
Efficiency Drives down costs, increases value for 
money
Increases transactions costs, requires spare capacity so 
is wasteful
Equity Gives benefits of choice to those 
currently disadvantaged and 
disempowered
Increases inequalities because disadvantaged people 
can’t take advantage of choice; choice isn’t feasible in 
rural areas
Patient empowerment Enhances patients’ influence and 
improves responsiveness
Many patients don’t want to choose; patients won’t travel; 
increases demand to unsustainable levels
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But government policy changed before the 
results of the pilot projects were published, and 
the hospital choice scheme that was rolled out 
in England differed from the pilot in many ways, 
not least in the much more limited availability 
of personal support and free transport and the 
fact that choice was to be offered to everyone at 
the point of referral, not to those already on the 
waiting list for elective surgery. Prices were fixed 
through the payment by results tariff system, and 
providers were expected to compete for patients 
by offering improved quality. This assumed that 
both general practitioners and patients would 
scan data on performance before making their 
referral decisions.
Regular surveys have monitored the scheme 
since its launch, and these show that patients’ 
awareness of the right to choose and general 
practitioners’ willingness to offer a choice have 
been slow to grow.6 Four years after the scheme 
was supposed to have been implemented nation‑
ally, only half of eligible patients were aware that 
they could choose a provider and less than half 
of those referred said they had been offered a 
choice. Recent evidence confirms the impression 
that most patients are keen on having a choice, 
even if they choose to remain at their local hos‑
pital, but many general practitioners remain 
ambivalent or antagonistic to the idea.7
The offer of choice seems to have intrinsic 
value to patients, even if they do not intend to 
switch providers. This is true for a majority of 
people in all social stratums, with older people, 
people with low educational qualifications, and 
those of mixed or non‑white ethnic backgrounds 
being especially likely to value choice. Despite a 
widespread view among general practitioners 
and hospital managers that choice is relevant 
only in urban centres, a King’s Fund study found 
that patients living in rural areas were both more 
likely to be offered a choice and more likely to 
choose to travel to a non‑local provider.7
Informed choice?
In theory, choice should drive quality improve‑
ments if providers have a financial incentive to 
attract patients and patients make use of reliable 
performance data to inform their decisions. The 
government in England has promised “an NHS 
information revolution,” with the publication 
of more detailed information on patients’ expe‑
rience, health outcomes, and safety indicators.2 
In practice, most patients have tended to rely on 
informal information sources, such as the opinion 
of their general practitioner, family, and friends 
or their own experience, with fewer than 1 in 10 
looking at officially published data on quality and 
performance. General practitioners also seem to 
prefer informal sources, with many indicating a 
distrust of official performance figures.7
Even in the United States, where choice and 
competition have been integral to health care for 
many years, there is little evidence that patients’ 
choices are influenced by published performance 
data.8 Nor is it evident that patient choice itself 
drives up quality standards, although the percep‑
tion of competition between hospitals does seem 
to have had an effect.9 This finding was reinforced 
by three recent studies of the effect of the NHS 
reforms.10‑12 These suggested that certain hospi‑
tals in areas where competition is more intense 
may have succeeded in attracting more patients, 
reducing preoperative lengths of stay, and reduc‑
ing mortality, although the mechanisms by which 
the changes were achieved, and indeed whether 
there is any causative link between these indica‑
tors, remains unclear.
The likely additional effect of allowing patients 
to choose between consultant led clinical teams 
is hard to gauge, although it will probably be 
popular with patients. The government wants 
other medical specialties to follow the lead set by 
cardiac surgeons and publish data on outcomes 
for individual named consultants. Each consult‑
ant surgeon’s survival rate for heart surgery is 
currently publicly available on the Care Quality 
Commission’s website (http://heartsurgery.cqc.
org.uk/Survival.aspx).13 Publication of these data 
seems to have led to improved performance with 
no evidence that surgeons are being more selec‑
tive about whom they treat.14 However, it seems 
likely that the effect of publication on clinical 
teams, rather than use of the data by patients, 
has driven the improvements. Since most patients 
don’t seem to use the information to shop around, 
it is unlikely that the improvements resulted 
from financial incentives. Professional pride and 
managerial targets may be the key, stimulated by 
a desire to maintain parity with benchmarks of 
best practice.
Choice of general practice
In March 2010 the Labour government launched 
a public consultation on extending choice in pri‑
mary care by removing practice boundaries, with 
an intention to implement this nationally by April 
2011.15 The coalition government has signalled 
its intention to proceed with these plans.2
NHS patients currently have the right to apply 
to register with a general practice of their choice, 
but practices can use their discretion about 
whether to accept a request. Refusals are usu‑
ally because the patient lives outside the prac‑
tice’s boundary area or because the practice 
has reached full capacity. In the new system the 
practice boundaries will be swept away, allow‑
ing patients to register with any practice of their 
choosing. Some people may want to register with 
practices near where they work, and some may 
want to join the lists of more than one practice, 
but since most patients value continuity and sur‑
veys suggest high levels of satisfaction with gen‑
eral practice care, it seems unlikely that many 
will want to switch.
For some years the Department of Health in 
England has been encouraging greater diversity 
and choice in primary care, but the effect of this 
on quality remains unclear. There are anecdotal 
accounts of service developments, including 
increased capacity in “under‑doctored” areas, 
extended opening hours, new forms of provider 
such as general practitioner led companies and 
social enterprises, and innovative services such 
as polyclinics and clinics for specific disad‑
vantaged groups—for example, travellers and 
homeless people.16 But it is not clear whether 
these developments can be reliably attributed 
to patients exercising choice or to other policy 
initiatives in play at the same time.
Choice of treatment
Although many people say they would like to 
be able to choose who to consult or where and 
when to be treated, provider choice is not at the 
top of most patients’ priorities.17  18 Most place 
greater value on involvement in choosing their 
treatment or care package. The government’s 
new commitment to shared decision making 
tackles this directly. Much more is known about 
the likely effect of this type of choice on patients’ 
experience and outcomes than about choice 
of provider because it has been extensively 
researched.
Shared decision making is a process in which 
patients are encouraged to participate in select‑
ing appropriate treatments or management 
options. Not being properly informed about 
their illness and the options for treatment are the 
most common causes of patient dissatisfaction.19 
Shared decision making is appropriate whenever 
there is more than one reasonable course of 
action and no single option is self evidently best 
for everyone. This situation is common because 
there are often different ways to treat a health 
problem, each of which may lead to different 
outcomes. These are known as “preference sen‑
sitive” decisions.20 In these cases, it is argued, 
the patient’s attitude to the likely benefits and 
risks should be a key factor in the decision.
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The white paper promises patients access to 
decision aids to support informed choice of treat‑
ment.2 Use of evidence based decision aids has 
been shown to lead to improvements in patients’ 
knowledge, better understanding of treatment 
options, more accurate perception of risks, and 
reduced demand for elective procedures.21 The 
idea of shared decision making attracts broad 
support from patients, professionals, and policy 
makers, but UK patients rarely get effective sup‑
port to make decisions.22 Clinicians have been 
slow to respond to the evidence that most patients 
want to participate in decisions about their care, 
citing concerns about time constraints and 
doubts about its relevance to their patients.23 The 
policy implies a challenge to entrenched attitudes 
and the need for big change in practice styles.
Conclusions
Choice has intrinsic value to patients. Most like 
the idea that they should be offered a choice of 
provider and, in particular, a choice of treatment. 
The evidence suggests that both can be benefi‑
cial, although there are risks. There are reasons 
to be concerned about the increasing complex‑
ity and fragmentation of healthcare delivery and 
the potential costs of providing greater diversity 
and choice. Nevertheless, the genie is out of the 
bottle and the expectation of choice will not go 
away. The task now is to develop effective means 
of engaging patients in healthcare decisions and 
of monitoring the outcomes.
Importantly, the availability of choice depends 
on the willingness of clinicians to offer it. They 
must ensure that patients understand the options 
and their likely consequences by pointing them 
to reliable information sources, eliciting their 
preferences, and facilitating their decisions. The 
evidence reviewed here suggests a reluctance 
on the part of general practitioners to play this 
supporting role, coupled with a gulf between 
what patients say they want and what general 
practitioners believe they want. This is worry‑
ing because the government’s plans assume that 
general practitioners understand patients’ prefer‑
ences and will commission services accordingly. 
Implementation of the plans for extending choice 
will be a major test of the effectiveness of general 
practitioner led commissioning.
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Tatarstan is a national republic 
in the Russian Federation. It 
is small by Russian standards 
(the size of the Netherlands), 
economically stable, and 
has an educated population. 
Recently a conference took place at the local 
medical academy entitled QIQUM: Quality 
Information for Quality Use of Medicines.
It would be trivial to write about this conference 
if it was a normal conference. However, the set up 
of this conference was rare in Russia: there was 
no drug industry support and not a single drug or 
device booth in the foyer. 
How is this possible in a country where the 
government is famous for never supporting the 
participation of doctors in conferences and for 
paying them wages that are 25% of the amount 
that bus drivers receive? In Europe only Russia 
and Ukraine pay doctors below average wages, 
and most influential medical academies fill their 
specialist conferences with industry sponsored 
symposia, specifically to make money.
The clinical pharmacology professor 
of the Tatarstan Medical Academy, Lilia 
Ziganshina, organised the conference. She 
was heavily influenced by Peter Mansfield and 
HealthySkepticism.org (previously MaLAM, 
the Medical Lobby for Appropriate Marketing), 
and she was serious about moving towards 
independent drug information that is free from the 
biases introduced by marketing. 
If I had been asked a year ago whether it is 
possible to arrange a big pharmacology meeting 
without industry support, I would have said that 
nobody will do it. It would be like being hungry at a 
table filled with free snacks. But it happened! We 
had the first conference of this kind, with no drug 
advertisements.
Of course, the conference was not perfect—life 
is not perfect. As well as the support received from 
educational institutes, it was sponsored by one 
of the big oil and gas companies and the biggest 
national publisher of medical books, Geotar.
Although this sponsorship might not be ideal, it 
represents much less of a conflict of interest than 
sponsorship from the pharmaceutical industry, 
which is why this conference was such a special 
event and worth paying attention to.
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